Description

ARA‑290 (Cibinetide; ARA 290)

• ARA‑290 (cibinetide) is a synthetic 11‑amino‑acid peptide derived from the helix B region of erythropoietin that selectively activates the tissue‑protective innate repair receptor (IRR) without stimulating erythropoiesis.
• Investigational therapeutic studied for anti‑inflammatory, tissue‑protective, and neuropathic‑pain benefits.

Key benefits (research findings)

• Reduces inflammation and limits tissue damage through IRR‑mediated cytoprotective signaling.
• Demonstrates neuroprotective and anti‑nociceptive effects in preclinical studies and clinical trials for small‑fiber neuropathy and neuropathic pain.
• May improve nerve function, reduce neuropathic pain symptoms, and enhance tissue repair in inflammatory disease models.
• Lacks the red‑blood‑cell/marrow stimulatory effects of full erythropoietin, lowering risk of erythropoiesis‑related adverse events.

Primary uses

• Investigational/clinical research for neuropathic pain syndromes (e.g., diabetic and sarcoidosis‑related small‑fiber neuropathy), inflammatory tissue injury, and trials evaluating tissue‑protective strategies.
• Mechanistic and translational studies probing IRR signaling, neuroprotection, and immunomodulation.

Suggested use (research/clinical context)

• Administer only per clinical‑trial or prescriber protocol (routes studied include subcutaneous injection); dosing, frequency, and duration are indication‑specific.
• Require specialist oversight with baseline and follow‑up assessments appropriate to the trial or treatment (pain scores, neuropathy testing, safety labs).

Safety and storage

• Safety profile: generally well tolerated in trials; reported adverse events are typically mild (injection‑site reactions, transient GI symptoms or headache). Erythropoietic stimulation is minimal due to IRR selectivity.
• Precautions: contraindications and special populations should be managed per protocol; avoid use outside approved studies. Discuss pregnancy/breastfeeding or active malignancy with treating clinicians.
• Handling/storage: store lyophilized peptide per manufacturer/supplier instructions (commonly refrigerated or frozen). Reconstitute with sterile diluent, aliquot as needed, minimize freeze–thaw cycles, protect from light and moisture, and follow sterility/aseptic handling and disposal procedures.

Quick facts

• Mechanism: selective activation of the innate repair receptor (IRR) → anti‑inflammatory, cytoprotective, neuroprotective signaling.
• Status: investigational with clinical trials for neuropathic and inflammatory indications; not a broadly approved therapy for general use.
• Procurement: available to research and clinical trial sites from legitimate suppliers under appropriate regulatory approvals.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.